Parabilis Medicines

Parabilis Medicines (formerly FogPharma) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, developing a new class of ultra-tunable alpha-helical peptide therapeutics called Helicons to reach intracellular protein targets long considered undruggable. Its AI- and physics-based discovery platform underpins a pipeline led by zolucatetide, a candidate targeting the beta-catenin / TCF interaction in the Wnt signaling pathway across multiple cancers. Backed by more than $500M from leading life sciences investors and public since its June 2026 IPO (Nasdaq: PBLS), the company was surfaced as a portfolio company of General Catalyst and GV. It publishes a public marketing and investor web presence and a science/data tech blog, but exposes no public developer API surface.

Parabilis Medicines is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Oncology, and Drug Discovery.

Parabilis Medicines’ developer surface includes engineering blog and 4 more developer resources.

🌐 Visit website 📡 Source on GitHub
14.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotechnologyPharmaceuticalsOncologyDrug DiscoveryPeptide TherapeuticsLife Sciences

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 14.3/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.4 / 20
Commercial Clarity 4.2 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/parabilis-medicines: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Parabilis Medicines Domain Security

TLSv1.3 · DNSSEC · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy
 TermsOfService
TermsOfService

Company 2

The organization behind the API

Website
Website
 Blog
Blog

Source (apis.yml)

apis.yml Raw ↑ 
aid: parabilis-medicines
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/parabilis-medicines.png
name: Parabilis Medicines
description: 'Parabilis Medicines (formerly FogPharma) is a clinical-stage biopharmaceutical company headquartered in Cambridge,
  Massachusetts, developing a new class of ultra-tunable alpha-helical peptide therapeutics called Helicons to reach intracellular
  protein targets long considered undruggable. Its AI- and physics-based discovery platform underpins a pipeline led by zolucatetide,
  a candidate targeting the beta-catenin / TCF interaction in the Wnt signaling pathway across multiple cancers. Backed by
  more than $500M from leading life sciences investors and public since its June 2026 IPO (Nasdaq: PBLS), the company was
  surfaced as a portfolio company of General Catalyst and GV. It publishes a public marketing and investor web presence and
  a science/data tech blog, but exposes no public developer API surface.'
url: https://raw.githubusercontent.com/api-evangelist/parabilis-medicines/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- general-catalyst
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Drug Discovery
- Peptide Therapeutics
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://parabilismed.com
- type: Blog
  url: https://parabilismed.com/tech-blog/
- type: PrivacyPolicy
  url: https://parabilismed.com/privacy-policy/
- type: TermsOfService
  url: https://parabilismed.com/terms-conditions/
- type: DomainSecurity
  url: security/parabilis-medicines-domain-security.yml
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 1
  pass: local-v1